8-K: Humacyte Announces Positive Phase 3 Dialysis Access Trial Results

Humacyte's Phase 3 V012 study of its acellular tissue engineered vessel (ATEV) for dialysis access in female patients met its primary endpoint, showing superior catheter-free days compared to standard AV fistula.

Summary

• Humacyte announced positive top-line interim results from its Phase 3 V012 clinical trial for its acellular tissue engineered vessel (ATEV) in female patients requiring hemodialysis.
• The study met its primary endpoint, demonstrating that ATEV provided an average of 91 more catheter-free days compared to the standard autologous arteriovenous (AV) fistula over 12 months.
• Patients receiving ATEV experienced significantly fewer infections, with a rate of 6 per 100 patient years compared to 23 per 100 patient years for AV fistula.
• Based on these results, Humacyte plans to terminate enrollment in the V012 study and will file a supplemental Biologics License Application (BLA) with the FDA in the second half of 2026.
• The target indication for the supplemental BLA is adult patients with end-stage kidney disease at increased risk of AV fistula maturation failure.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, with the ATEV meeting its primary endpoint in a Phase 3 trial and demonstrating significant improvements over the standard of care in terms of efficacy and safety.

Positives

• The ATEV met the primary endpoint of the V012 Phase 3 study, demonstrating superiority in catheter-free days (91 more days) compared to AV fistula.
• The ATEV showed a statistically significant reduction in dialysis access infections, with 17 fewer infections per 100 patient-years compared to AV fistula.
• The study met its pre-specified superiority threshold with a p-value of 0.00070 for the primary endpoint.
• ATEV demonstrated consistent advantages over AV fistula in multiple secondary efficacy endpoints.
• The overall benefit-risk safety profile of the ATEV was observed to be favorable, with no new or unexpected safety signals identified.
• Humacyte's acellular tissue engineered vessel (ATEV) for vascular injury indication (Symvess) was approved by the FDA in December 2024.
• The company has received Regenerative Medicine Advanced Therapy (RMAT) designations for its 6mm ATEV for AV access in hemodialysis and for advanced PAD.

Negatives

• While the ATEV showed fewer infections, the interim analysis reported 2 events (6 per 100 patient years) for ATEV versus 9 events (23 per 100 patient years) for AV fistula.
• The V012 study is an open-label, randomized study, which can introduce bias.
• The target indication for the supplemental BLA is specific to adult patients at increased risk of AV fistula maturation failure, potentially limiting the initial market.

Risks

• The forward-looking statements are subject to significant risks and uncertainties, including changes in applicable laws or regulations, and other economic, business, competitive, and reputational factors.
• There is a possibility that Humacyte may be adversely affected by other economic, business, competitive, and/or reputational factors.
• The company's ability to manufacture Symvess and other product candidates in sufficient quantities to satisfy clinical trial and commercial needs is a potential risk.
• Market acceptance of ATEVs and the availability of third-party coverage and reimbursement are key uncertainties.
• The company's ability to obtain and maintain intellectual property protection for its product candidates and operate without infringing on others' intellectual property rights is a risk.
• Future financial performance and capital requirements are subject to various risks and uncertainties.

Future Outlook

Humacyte plans to file a supplemental Biologics License Application (BLA) with the FDA in the second half of 2026 for the ATEV in adult patients with end-stage kidney disease who are at increased risk of AV fistula maturation failure. The company also has a pipeline of other regenerative medicine products in various stages of development, including for vascular trauma, peripheral artery disease, and coronary artery bypass grafting.

Management Comments

• "We are excited to announce positive clinical results for the Phase 3 V012 study, particularly as these results represent a real advancement in the dialysis care for female patients, a population that currently has suboptimal access options."
• "Patients receiving an ATEV had an average of three months additional catheter-free time as compared to AV fistula, a highly significant outcome."
• "Reducing patients reliance on catheters is critical given the high risk of infection and complications seen with indwelling catheters."
• "These results reinforce the potential of our bioengineered human blood vessel to improve outcomes while addressing longstanding challenges in dialysis access."

Industry Context

StockSavvy.ai notes that Humacyte's positive Phase 3 results for its ATEV in dialysis access align with the industry's ongoing efforts to develop safer and more effective long-term vascular access solutions, particularly for patient populations with unmet needs like female hemodialysis patients. The company's focus on bioengineered, universally implantable tissues positions it within the growing regenerative medicine sector.

Comparison to Industry Standards

• The V012 study directly compares Humacyte's ATEV against the current standard of care, autologous arteriovenous (AV) fistula, for dialysis access.
• The ATEV demonstrated superior catheter-free days (91 more days) and a lower infection rate (17 fewer per 100 patient-years) compared to AV fistula.
• In the V007 Phase 3 trial for dialysis access, ATEV also showed superior functional patency at 6 months (81.3% vs. 66.4%) and secondary patency at 12 months (68.3% vs. 62.2%) compared to AV fistula.
• For vascular trauma, Symvess (ATEV) showed a lower conduit infection rate (0.9% vs. 8.4%) and amputation rate (4.5% vs. 24.3%) compared to a synthetic graft benchmark in combined civilian and military studies.

Stakeholder Impact

• Shareholders: Positive clinical results are likely to be viewed favorably, potentially impacting stock price.
• Patients: Improved outcomes through increased catheter-free days and reduced infection rates for female hemodialysis patients.
• Healthcare System: Potential for lower dialysis costs due to reduced complications and hospitalizations associated with infections.
• Physicians: Provides a new, potentially superior option for dialysis access, especially for female patients with unmet needs.

Next Steps

• Humacyte plans to file a supplemental Biologics License Application (BLA) with the FDA during the second half of 2026.
• Existing patients in the V012 study will continue to be followed as per protocol.
• Results from the V012 Phase 3 study will be presented at the Society for Vascular Surgery's (SVS's) Vascular Annual Meeting (VAM) on June 11, 2026.
• Humacyte is developing a pipeline of other regenerative medicine products, with milestones including U.S. commercial launch growth for Symvess, publication of V007 Phase 3 results, and commencement of first-in-human studies for CTEV and BVP.

Key Dates

Recommendation

The positive Phase 3 results for the ATEV in dialysis access, demonstrating superiority in catheter-free days and reduced infection rates, coupled with the planned FDA filing and a strong pipeline, represent a significant de-risking event and a substantial growth opportunity for Humacyte. This clinical success strongly supports a positive outlook for the company's lead product candidate.

Keywords

Humacyte, ATEV, V012 study, Phase 3 trial, Dialysis access, End-stage renal disease, AV fistula, Biologics License Application